Investor Relations

Latest Financial Results

Q3 2020

Quarter Ended May 31, 2020

Latest Annual Filing

For Fiscal Year Ending Aug 31, 2019

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Agentix Biopharma is a biotechnology company focused on the development of synthetic agonists, inverse agonists and antagonists which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. GPCRs are considered the largest family of proven therapeutic targets. To date there are over 134 drugs approved in the United States or the European Union which target GPCRs generating several billion dollars annually in revenues for pharmaceutical companies.[1]

Agentix Biopharma has developed partnerships with leading academic and research institutions. Agentix Biopharma has exclusively licensed patented, synthetically-derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. Agentix Biopharma is advancing these therapeutic product candidates in clinical trials.

[1] Sriram, K. & Insel, P., “G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?”, Molecular Pharmacology, 93:251–258, April 2018.

Investor Contact Information

Company

Agentix Corp.
32932 Pacific Coast Highway
Dana Point, CA 92629

Investor Relations

ir@agentixcorp.com

Transfer Agent

West Coast Stock Transfer, Inc.
721 N. Vulcan Avenue
#205
Encinitas, CA 92024
cs@wcsti.com